

June 29, 2016

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (DE-89)	PAMREVLUMAB
PRONUNCIATION	pam rev' lue mab
THERAPEUTIC CLAIM	Treatment of hepatic fibrosis, idiopathic pulmonary fibrosis, diabetic nephropathy
CHEMICAL NAMES	

1. Immunoglobulin G1, anti-(human connective tissue growth factor) (human monoclonal FG-3019 heavy chain), disulfide with human monoclonal FG-3019 k-chain, dimer
2. Immunoglobulin G1-kappa, anti-[Homo sapiens CTGF (connective tissue growth factor, CCN family member 2, CCN2, hypertrophic chondrocyte-specific protein 24, HCS24, insulin-like growth factor-binding protein 8, IGFBP-8)], Homo sapiens monoclonal antibody; gamma1 heavy chain (1-449) [Homo sapiens VH (IGHV3- 48*03 (84.70%) -(IGHD)-IGHJ4*01) [8.7.14] (1-120) - IGHG1*03, G1m3 (CH1 (121-218), hinge (219-233), CH2 (234-343), CH3 (344-448), CHS K2>del (449)) (121-449)], (223-214')-disulfide with kappa light chain (1'-214') [Homo sapiens V-KAPPA (IGKV1D-16*01 (100.00%) - IGKJ2*01) [6.3.9] (1'-107') -IGKC*01, Km3 (108'-214')]; dimer (229- 229":232-232")-bisdisulfide

STRUCTURAL FORMULA

Heavy chain / Chaîne lourde / Cadena pesada

EGQLVQSGGG	LVHPGGSRLR	SCAGSGFTFS	SYGMHWVRQA	PGKLEWVSG	50
IGTGGGTYST	DSVKGRFTIS	RDNAKNSLYL	QMNSLRAEDM	AVYYCARGDY	100
YSGSGFFDCW	GQGLVTVSS	ASTKGPSVFP	LAPSSKSTSG	GTAALGCLVK	150
DYFPEPVTVS	WNSGALTSKV	HTFPAVLQSS	GLYSLSSVVT	VPSSSLGTQT	200
YICNVNHNKPS	NTKVDKRVEP	KSCDKTHTCP	PCPAPELLGG	PSVFLFPPKP	250
KDTLMISRTP	EVTCVVVDVS	HEDPEVKFNW	YVDGVEVHNA	KTKPREEQYN	300
STYRVVSVLT	VLHQDWLNGK	EYKCKVSNKA	LPAPIEKTIS	KAKGQPREPQ	350
VYTLPPSREE	MTKNQVSLTC	LVKGFYPSDI	AVEWESNGQP	ENNYKTTTPV	400
LDSGDGSFFLY	SKLTVDKSRW	QQGNVFSCSV	MHEALHNHYT	QKSLSLSPG	449

Light chain / Chaîne légère / Cadena ligera

DIQMTQSPSS	LSASVGDRTV	ITCRASQGIS	SWLAWYQQKP	EKAPKSLIYA	50'
ASSLQSGVPS	RFSGSGSGTD	F'LTLSLQLP	EDFATYYCQQ	YNSYPPTFGQ	100'
GTKLEIKRTV	AAPSVFIFPP	SDEQLKSGTA	SVVCLLNNFY	PREAKVQWKV	150'
DNALQSGNSQ	ESVTEVDQSKD	STYSLSSSTLT	LSKADYEEKHK	VYACEVTHQG	200'
LSSPVTKSFN	RGEC				214'

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

22-95	22''-95''	23-88''	23'''-88'''	134'-194''	134'''-194'''	147-203	147''-203''
214'-223	214'''-223'''	229-229''	232-232''	264-324	264'''-324'''	370-428	370-428''

Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)

Asn300 Asn300''

MOLECULAR FORMULA	$C_{6492}H_{10018}N_{1718}O_{2086}S_{48}$
MOLECULAR WEIGHT	147.0 kDa
TRADEMARK	None as yet
SPONSOR	FibroGen, Inc.
CODE DESIGNATIONS	FG-3019
<u>CAS</u> REGISTRY NUMBER	946415-13-0
UNII	QS5F6VTS00
WHO NUMBER	10060

gbk